JOHN KIRKWOOD to Carboplatin
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Carboplatin.
Connection Strength
0.394
-
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
Score: 0.124
-
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20; 31(3):373-9.
Score: 0.103
-
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol. 2002 Dec; 50(6):433-44.
Score: 0.051
-
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999 May 01; 85(9):1979-84.
Score: 0.040
-
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
Score: 0.028
-
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One. 2013; 8(8):e69748.
Score: 0.027
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
Score: 0.020